

GlaxoSmithKline (UK Ltd) and Our Health Partnership Executive Summary

COPD: Risk Stratification and management optimisation in line with national guidelines and local formulary and strategy

This summary has been written by GSK with consultation and approval from the Joint Working Project Team.

Our Health Partnership and GSK are undertaking a Joint Working project. The aims are to:

- Prioritise patients with risk factors for review.
- Ensure alignment to national NICE COPD management and prescribing guidelines.
 - Emphasising the importance of high-impact low-cost interventions for all (‘flu vaccination, smoking cessation support, pulmonary rehabilitation referral) and of inhaler technique check and self-management plans.
 - Reinforcing the appropriate use of triple therapy as guided by the NICE guideline.
 - Ensure patients receive appropriate therapy in line with national guidelines.
 - Minimise the number of inhalers and the number of different types of inhaler used by each person as far as possible.
 - Prescribing in line with local formulary.
- Align to the national prescribing strategy, Investment and Impact Fund ‘Help create a more sustainable NHS’ enhanced service where clinically appropriate for patients.

This involves a balance of contributions from both parties with the pooling of skills, experience and resources. The project will run from April 2022 – February 2023. GSK will fund patient reviews via Interface Clinical Services (ICS) Ltd in up to 21 practices at an approximate cost of £8,967 per practice, to a total of approximately £188,305. In addition, GSK will contribute a total of approximately £17,200 in indirect costs such as colleagues’ time across the project. GSK will not have any influence over treatment decisions. GSK will not have access to patient medical records or personal information.

The NHS will contribute up to approximately 1400 hours of resource across primary care colleagues’ time and GP Federation project management time at an approximate indirect cost of £4,574 per practice in up to 21 practices, to a total of approximately £96,041. The NHS contribution to the project does not include any transfer of money, it is based on the approximate costs of resource allocation.

Intended Benefits:

Patients	<ul style="list-style-type: none"> • Full review in line with national guideline based on current therapy and risk stratification (patients may have not received a review otherwise or will receive quicker than when reviewed in yearly cycle) potentially increasing volume of those receiving a review, potentially leading to better outcomes. • Optimisation of both non-pharmacological & pharmacological management. • Potentially fewer COPD- related interventions, including hospital admissions. • Better informed about COPD management and treatment options. • COPD managed in accordance with current best practice clinical guidance. • Better experience of the healthcare system – access to an Interface Clinical Service Clinical pharmacist and/or upskilled primary care clinician at their own GP practice.
NHS	<ul style="list-style-type: none"> • Realisation of value-based healthcare objectives of improved patient outcomes with reduced costs. • Support with risk stratification. • Additional resource support. • Guideline implementation resulting in consistent prescribing and non-prescribing recommendations and promoting for sustainability. • Insight into COPD population at practice and federation to allow sharing best practice and evaluation of care provision to support clinical governance and support equity of care. • Opportunity to upskill primary care doctors and nurses. • Prescribing inline with national sustainability aspirations where clinically appropriate for patients. • An environment to support the delivery of improved health outcomes for the COPD patient population. • Potential reduction in COPD- related interventions, including hospital admissions.
GSK	<ul style="list-style-type: none"> • Helps GSK to live its value of being a patient focussed company. • Demonstrate partnership working. • Expansion of the COPD patient population who are managed according to current clinical and best practice guidelines as a result of the programme.

GlaxoSmithKline (UK Ltd) and Our Health Partnership Executive Summary

	<ul style="list-style-type: none">• Potential increase in prescribing of on-formulary dry powder inhaler products within class if clinically appropriate for patients, aligned to the sustainability agenda – which may include GSK products.• Increase in the appropriate use of medicines licensed for COPD aligned to local guidance, will likely increase the prescribing of GSK products as well as those of other pharmaceutical companies.• Better understanding of the challenges faced by the NHS in delivering high-quality patient services and care.• Broadening of professional network.
--	--